News Summary

In 2024, Canadian venture capital (VC) funding witnessed a boost, largely due to significant megadeals, despite continued challenges at the seed-stage level. The Canadian Venture Capital Association’s (CVCA) report highlighted a total of $7.86 billion CAD invested across 592 deals, marking a 10% increase in dollar value from the previous year. This was heavily influenced by Vancouver-based Clio’s historic $1.24-billion Series F round, which, along with other major deals, accounted for 62% of all VC investments. Without these megadeals, overall funding would have seen a decline.

Seed-stage funding presented a stark contrast, with a 47% drop in the number of deals compared to 2023, raising concerns about the future pipeline of high-growth startups in Canada. Despite the reduction in seed-stage activity, later-stage funding saw substantial support, particularly from government-backed and pension funds such as BDC, Export Development Canada, and Fonds de solidarité FTQ. BDC Capital’s recent announcement of nearly $1 billion in new commitments for later-stage companies underscores the focus on sustaining high-performing firms within Canada.

The Information, Communications & Technology (ICT) sector continued to dominate investment interests, while the life sciences sector also recorded significant growth, driven by notable exits such as AstraZeneca’s $3.26-billion acquisition of Fusion Pharmaceuticals. This acquisition was the largest exit of the year, representing a significant portion of the total exit value. The overall exit landscape in Canada, however, experienced a decline in 2024 with reduced M&A activity and no IPOs. As economic uncertainties persist, future Canadian VC fundraising remains unpredictable.